LOS ANGELES–(BUSINESS WIRE)–$NKTR #ClassAction—The
Schall Law Firm, a national shareholder rights litigation firm,
announces the filing of a class action lawsuit against Nektar
Therapeutics (“Nektar” or “the Company”) (NASDAQ: NKTR)
for violations of §§10(b) and 20(a) of the Securities Exchange Act of
1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and
Investors who purchased the Company’s shares between November 11, 2017
and October 2, 2018, inclusive (the ”Class Period”), are encouraged to
contact the firm before December 31, 2018.
If you are a shareholder who suffered a loss, click
here to participate.
We also encourage you to contact Brian Schall, or Sherin Mahdavian, of
the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA
90067, at 424-303-1964, to discuss your rights free of charge. You can
also reach us through the firm’s website at www.schallfirm.com,
or by email at firstname.lastname@example.org.
The class, in this case, has not yet been certified, and until
certification occurs, you are not represented by an attorney. If you
choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading
statements to the market. Nektar’s clinical-stage drug NKTR-214 faced
multiple issues, and the Company’s attempt to improve it by “pegylating”
IL-2 failed. The Company did not disclose that previous studies
attempting to pegylate IL-2 also failed. The extended half-life for
NKTR-214 was unlikely to provide benefits and also created safety
concerns. NKTR-214 was less effective than IL-2 by itself. Based on
these facts, the Company’s public statements were false and materially
misleading throughout the class period. When the market learned the
truth about Nektar, investors suffered damages.
the case to recover your losses.
The Schall Law Firm represents investors around the world and
specializes in securities class action lawsuits and shareholder rights
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and rules of ethics.